Patents by Inventor Hugo Mouquet
Hugo Mouquet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230340081Abstract: The invention provides anti-S-HBs antibodies and methods of using the same.Type: ApplicationFiled: June 8, 2021Publication date: October 26, 2023Inventors: Maryline BOURGINE, Maxime BERETTA, Hugo MOUQUET, Verena HEHLE, Stanislas POL, Hélène STRICK-MARCHAND, Malika AIT-GOUGHOULTE, Nadège PELLETIER, Jens FISCHER, Guy GEORGES, Tilman SCHLOTHAUER, Erwin VAN PUIJENBROEK, Wouter DRIESSEN
-
Publication number: 20230279082Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: ApplicationFiled: April 7, 2023Publication date: September 7, 2023Applicants: The Rockefeller University, California Institute of TechnologyInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Patent number: 11649276Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: GrantFiled: September 9, 2021Date of Patent: May 16, 2023Assignees: The Rockefeller University, California Institute of TechnologyInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Publication number: 20220002390Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: ApplicationFiled: September 9, 2021Publication date: January 6, 2022Applicants: The Rockefeller University, California Institute of TechnologyInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Patent number: 11142564Abstract: The present invention relates to anti-HW antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immuno suppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: GrantFiled: July 10, 2019Date of Patent: October 12, 2021Assignees: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Publication number: 20190345233Abstract: The present invention relates to anti-HW antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immuno suppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: ApplicationFiled: July 10, 2019Publication date: November 14, 2019Applicants: The Rockefeller Universtiy, California Institute of TechnologyInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Patent number: 10392433Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: GrantFiled: June 12, 2018Date of Patent: August 27, 2019Assignees: The Rockefeller University, California Institute of TechnologyInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Publication number: 20180282400Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: ApplicationFiled: June 12, 2018Publication date: October 4, 2018Applicant: The Rockefeller UniverstiyInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Patent number: 10047146Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: GrantFiled: October 18, 2013Date of Patent: August 14, 2018Assignee: The Rockefeller UniversityInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
-
Publication number: 20150274813Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.Type: ApplicationFiled: October 18, 2013Publication date: October 1, 2015Applicants: THE ROCKEFELLER UNIVERSITY, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
